Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs

Vernaz-Hegi, Nathalie; Agoritsas, Thomas; Calmy, Alexandra; Gayet-Ageron, Angèle; Gold, Gabriel; Perrier, Arnaud; Picard, Fabienne; Prendki, Virginie; Reny, Jean-Luc; Samer, Caroline Flora; Stirnemann, Jérôme; Vetter, Pauline; Zanella, Marie-Céline; Zekry Berger, Dina Selma; Baggio, Stéphanie

doi:10.4414/smw.2020.20446

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs
Authors		Vernaz-Hegi, Nathalie Agoritsas, Thomas Calmy, Alexandra Gayet-Ageron, Angèle Gold, Gabriel Perrier, Arnaud Picard, Fabienne Prendki, Virginie Reny, Jean-Luc Samer, Caroline Flora Stirnemann, Jérôme Vetter, Pauline Zanella, Marie-Céline Zekry Berger, Dina Selma Baggio, Stéphanie show all authors [1 - 15]
Published in		Swiss Medical Weekly. 2020, vol. 150, w20446
Abstract		Hydroxychloroquine and lopinavir/ritonavir have been used as experimental therapies to treat COVID-19 during the first wave of the pandemic. Randomised controlled trials have recently shown that there are no meaningful benefits of these two therapies in hospitalised patients. Uncertainty remains regarding the potential harmful impact of these therapies as very early treatments and their burden to the health care system. The present study investigated the length of hospital stay (LOS), mortality, and costs of hydroxychloroquine, lopinavir/ritonavir or their combination in comparison with standard of care among patients hospitalised for coronavirus disease 2019 (COVID-19).
Keywords		Adolescent — Adult — Age Factors — Aged — Aged, 80 and over — Antiviral Agents/administration & dosage/adverse effects/therapeutic use — COVID-19/drug therapy/epidemiology/mortality — Child — Child, Preschool — Comorbidity — Drug Combinations — Drug Therapy, Combination — Health Expenditures — Hospital Mortality/trends — Humans — Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use — Infant — Length of Stay/statistics & numerical data — Lopinavir/administration & dosage/adverse effects/therapeutic use — Middle Aged — Pandemics — Retrospective Studies — Ritonavir/administration & dosage/adverse effects/therapeutic use — SARS-CoV-2 — Severity of Illness Index — Sex Factors — Socioeconomic Factors — Therapies, Investigational/methods — Young Adult
Identifiers		DOI: 10.4414/smw.2020.20446 PMID: 33382449
Full text		Article (Published version) (822 Kb) - Free access Other version: https://smw.ch/article/doi/smw.2020.20446
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires Faculté de médecine / Centre de recherche clinique
Research groups		Epidémiologie clinique et biostatistique (115) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) Pharmaco-omiques et médecine de précision (1003) VIH/SIDA (930) Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
Citation (ISO format)		VERNAZ-HEGI, Nathalie et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. In: Swiss Medical Weekly, 2020, vol. 150, p. w20446. doi: 10.4414/smw.2020.20446 https://archive-ouverte.unige.ch/unige:151585